What Is the SCL-70 Antibody Test? The SCL-70 antibody test is a blood test used to detect antibodies against topoisomerase I, an enzyme found in the nucleus of cells. These antibodies are part of the antinuclear antibody (ANA) family and are often associated with certain autoimmune conditions—most notably systemic sclerosis (scleroderma). This test helps doctors evaluate symptoms such as skin thickening, joint pain, fatigue, or shortness of breath that may be related to autoimmune diseases. Reference Range: < 1.0 AI (Antibody Index) — Negative <1.0 AI: Negative (normal) 1.0–1.5 AI: Borderline >1.5 AI: Positive (elevated antibody levels) AI (Antibody Index) is a standardized unit that reflects the strength or concentration of antibodies in the blood. What Does a Positive or Elevated SCL-70 Antibody Mean? A positive SCL-70 antibody result (AI ≥ 1.0) may indicate an autoimmune response, particularly: Systemic sclerosis (diffuse scleroderma) – a chronic autoimmune disease that causes hardening and tightening of the skin and can affect internal organs like the lungs and kidneys. The presence of SCL-70 antibodies is most strongly linked to the diffuse cutaneous form of scleroderma and may correlate with lung involvement (pulmonary fibrosis). However, a positive result does not confirm a diagnosis on its own. It must be interpreted alongside clinical symptoms, physical examination, and other tests (like ANA, anti-centromere antibodies, and imaging). What Does a Negative SCL-70 Antibody Result Mean? A result below 1.0 AI is considered negative, suggesting that SCL-70 antibodies were not detected in the blood. This lowers the likelihood of systemic sclerosis but does not completely rule out autoimmune disease, as other antibodies may be involved. When Is This Test Ordered? Your healthcare provider may order the SCL-70 antibody test if you’re experiencing symptoms such as: Thickened or tight skin Raynaud’s phenomenon (fingers turning white or blue in cold) Joint or muscle pain Shortness of breath or signs of lung involvement Fatigue or gastrointestinal symptoms In summary, the SCL-70 antibody test is a valuable tool in diagnosing and monitoring systemic sclerosis, especially its diffuse form. A positive result warrants further evaluation by a rheumatologist to determine the underlying cause and appropriate treatment.
ADMA/SDMA may be measured in individuals with multiple risk factors for the development of CVD. SDMA is primarily excreted in the urine and identifies reduced renal function. One of the earliest manifestations of endothelial dysfunction is nitric oxide (NO) deficiency, which promotes atherosclerosis. Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), its structural isomer, are metabolites of L-arginine, an amino acid that is catalyzed to L-citrulline and NO by nitric oxide synthase (NOS). Both ADMA and SDMA have distinct pathophysiologies and manifestations. ADMA is a competitive inhibitor of NOS thereby reducing NO production and promoting endothelial dysfunction. SDMA also interferes with NO production, but does so indirectly by reducing the cellular availability of arginine. ADMA is primarily cleared through enzymatic degradation in the bloodstream and its presence identifies subclinical cardiovascular disease (CVD). Conversely, SDMA is primarily excreted in the urine and identifies reduced renal function. Interpretation: ADMA: Low // SDMA: Low Normal endothelial function Med High Low ADMA: Med / High // SDMA: Low Endothelial dysfunction and possible presence of pre-diabetes/diabetes or CVD ADMA: Low // SDMA: High Reduced renal function ADMA: Med / High // SDMA: High - Endothelial dysfunction and possible presence of pre-diabetes/diabetes or CVD - Reduced renal function References: American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care 1 January 2022; 45 (Supplement_1): S125–S143. https://doi.org/10.2337/dc22-S009
breakdown product of fatty acids.
Fatty acid oxidation + Carnitine
breakdown product of fatty acids.
Fatty acid oxidation + Carnitine
breakdown product of fatty acids
A marker of gut secretory immunity and barrier function.
Mucosal immune antibody measuring gut immune defense activity in stool.
Immune Response
A marker of gut secretory immunity and barrier function.
Immune Response
also known as the erythrocyte sedimentation rate (ESR)
Mature neutrophils on the CBC differential; elevation signals infection.
Mature infection-fighting white blood cells